secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bellerophon Therapeutics, Inc. (—)
CIK:        0001600132
Form:       8-K
Filed at:   2023-10-13T23:59:59+00:00
Accession:  0001104659-23-108988
Event type: other_material
Sentiment:  negative
Materiality: 0.95
Item codes: 3.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bellerophon to dissolve and liquidate after Nasdaq delisting; trading suspended Oct 16
--------------------------------------------------------------------------------

- Nasdaq will suspend trading of BLPH common stock at open on Oct 16, 2023 after company failed to meet listing conditions.
- Board approved a plan of liquidation and dissolution on Oct 12, 2023, subject to stockholder approval at a special meeting.
- Company will cease business operations and distribute remaining assets to stockholders after paying all claims and obligations.
- Stockholders are not entitled to appraisal rights; stock will be cancelled after final distributions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1600132/000110465923108988/0001104659-23-108988-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1600132/000110465923108988/tm2328395d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-108988

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer